EDMONTON, ALBERTA--(CCNMatthews - April 24, 2006) - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced the appointment of Scott M. Langille as Chief Financial Officer effective May 2, 2006.
